Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer

BACKGROUND: There are few third-line or later (3L+) treatment options for advanced/metastatic (adv/met) gastric cancer/gastroesophageal junction cancers (GC/GEJC). 3L+ Nivolumab demonstrated encouraging results in Asian patients in the ATTRACTION-2 study compared with placebo (12-month survival, 26%...

Descripción completa

Detalles Bibliográficos
Autores principales: Chau, Ian, Le, Dung T., Ott, Patrick A., Korytowsky, Beata, Le, Hannah, Le, T. Kim, Zhang, Ying, Sanchez, Teresa, Maglinte, Gregory A., Laurie, Melissa, Abraham, Pranav, Patel, Dhiren, Shangguan, Tong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942583/
https://www.ncbi.nlm.nih.gov/pubmed/31549264
http://dx.doi.org/10.1007/s10120-019-01008-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942583/
https://www.ncbi.nlm.nih.gov/pubmed/31549264
http://dx.doi.org/10.1007/s10120-019-01008-9

Ejemplares similares